Iovance Biotherapeutics, Inc. - Common Stock (IOVA)
2.1800
-0.0600 (-2.68%)
NASDAQ · Last Trade: Oct 18th, 3:48 AM EDT
Detailed Quote
Previous Close
2.240
Open
2.190
Bid
2.160
Ask
2.190
Day's Range
2.130 - 2.240
52 Week Range
1.639 - 12.51
Volume
9,469,566
Market Cap
665.45M
PE Ratio (TTM)
-1.787
EPS (TTM)
-1.2
Dividend & Yield
N/A (N/A)
1 Month Average Volume
10,860,334
Chart
About Iovance Biotherapeutics, Inc. - Common Stock (IOVA)
Iovance Biotherapeutics is a clinical-stage biotechnology company focused on the development and commercialization of novel cell therapy products for the treatment of cancer. The company specializes in the use of tumor-infiltrating lymphocyte (TIL) therapy, which harnesses the body’s immune system to target and destroy cancer cells. By processing and expanding patients' own immune cells, Iovance aims to create personalized therapies that can provide effective options for those with various types of solid tumors. Their innovative approach leverages advancements in cell therapy to improve patient outcomes and contribute to the evolving landscape of cancer treatment. Read More
SAN CARLOS, Calif., Oct. 17, 2025 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) ("Iovance" or the “Company”), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (“TIL”) therapies for patients with cancer, today announced that on October 16, 2025 (the “Date of Grant”), the Company approved the grant of inducement stock options covering an aggregate of 62,790 shares of Iovance’s common stock to nine new, non-executive employees.
October 17, 2025 – In the volatile world of biotechnology, ambitious price targets often fuel investor speculation and market buzz. However, for Turnstone Biologics Corp. (NASDAQ: TSTN), the notion of its stock reaching a $100 valuation stands in stark contrast to its current precarious financial and operational state. Despite the transformative
Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Iovance (IOVA) To Contact Him Directly To Discuss Their Options
SAN CARLOS, Calif., Sept. 19, 2025 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) ("Iovance" or the “Company”), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (“TIL”) therapies for patients with cancer, today announced that on September 18, 2025 (the “Date of Grant”), the Company approved the grant of inducement stock options covering an aggregate of 22,810 shares of Iovance’s common stock to two new, non-executive employees.
NetworkNewsWire Editorial Coverage : Progress in RNA-based medicines, immunotherapies and targeted treatments is not simply desirable, it is a critical necessity. Deadly cancers such as glioblastoma and pancreatic cancer remain among the hardest to treat, while rare pediatric disorders still take a tragic toll on young patients each year. Against this backdrop of significant unmet need, Oncotelic Therapeutics Inc. (OTCQB: OTLC) ( Profile ) distinguishes itself. Guided by the forward-looking leadership of chair and CEO Dr. Vuong Trieu, the company is applying AI, nanomedicine and innovative clinical approaches to reimagine biotechnology. Anchored by a strong intellectual property portfolio, including some 500 patent applications and 75 granted patents, Oncotelic is assembling a pioneering pipeline designed to transform how cancer and rare diseases are treated. In doing so, it positions itself among the innovators — including Iovance Biotherapeutics Inc. (NASDAQ: IOVA), Merck & Co. Inc. (NYSE: MRK), AstraZeneca PLC (NASDAQ: AZN) and Bristol-Myers Squibb Co. (NYSE: BMY) — that are driving advances…
SAN CARLOS, Calif., Aug. 29, 2025 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, today announced that senior leadership plans to present at the following conferences:
SAN CARLOS, Calif., Aug. 22, 2025 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) ("Iovance" or the “Company”), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (“TIL”) therapies for patients with cancer, today announced that on August 21, 2025 (the “Date of Grant”), the Company approved the grant of inducement stock options covering an aggregate of 182,370 shares of Iovance’s common stock to 20 new, non-executive employees.
As the regular session of the US market concludes on Monday, let's get an insight into the after-hours session and identify the stocks leading the pack in terms of gains and losses.
